Abbott (ABT) Q4 2025: Medical Device Growth Hits 10.5% as Nutrition Recalibration Weighs on Outlook
Abbott’s Q4 revealed a decisive pivot toward medical device innovation and margin expansion, while the nutrition segment’s volume challenges forced a recalibration of near-term growth expectations. Leadership’s readiness to absorb short-term pain in nutrition to restore sustainable volume growth signals a willingness to trade immediate results for long-term health. The 2026 setup hinges on execution in launching new products and integrating Exact Sciences, with margin discipline and pipeline velocity as key levers.
Summary
- Nutrition Reset: Abbott is actively shifting pricing and promotion to revive volume growth, accepting short-term pain to restore long-term health.
- Medical Device Momentum: Diabetes, electrophysiology, and structural heart franchises are delivering sustained double-digit growth, underpinned by pipeline execution.
- Margin Discipline: Operating margin expansion continues, supporting Abbott’s double-digit EPS growth targets despite top-line moderation.
Performance Analysis
Abbott’s Q4 performance was defined by strong double-digit growth in medical devices, with diabetes care, electrophysiology, and structural heart all posting robust gains. The diabetes franchise, driven by continuous glucose monitoring (CGM) adoption, exceeded $7.5 billion in annual sales, marking a third consecutive year of billion-dollar-plus growth. Electrophysiology (EP), boosted by the Volt PFA catheter and TactiFlex Duo launches, maintained double-digit momentum in both the US and international markets. Structural heart and rhythm management segments also outperformed, with leadless pacemaker Aver capturing early share in a large $10 billion market.
However, nutrition sales declined in the quarter, reflecting both the loss of a major contract and a broader volume slowdown as price-sensitive consumers pushed back against higher prices. Management initiated price and promotion actions in Q4, with the expectation that these will suppress near-term growth but position the business for a return to volume-driven expansion by the second half of 2026. Diagnostics, excluding COVID testing, saw modest growth, with CoreLab and point-of-care segments offsetting China headwinds. Emerging markets, particularly EPD (Established Pharmaceuticals Division), continued to deliver high single-digit growth, supported by biosimilar launches and strong demand in India, Latin America, and the Middle East.
- Device Franchise Outperformance: Diabetes, EP, and structural heart posted double-digit growth, offsetting weakness in nutrition and COVID testing.
- Nutrition Drag: Volume declines from price sensitivity and contract loss weighed on top-line growth, with leadership choosing to reset pricing strategy.
- Operating Margin Expansion: Despite tariff and cost pressures, adjusted operating margin rose 150 basis points, reflecting cost control and product mix improvement.
Abbott’s ability to drive margin expansion while investing in pipeline launches and absorbing nutrition headwinds underscores the underlying strength in its diversified portfolio.
Executive Commentary
"Our goal is to transition our business back to one with a more balanced growth profile, with volume growth playing a greater role going forward... these are the right steps to take to better position the business for longer term success."
Robert Ford, Chairman and Chief Executive Officer
"We continue to look at a 50 to 70 basis point improvement in operating margins every year and that's kind of what we've got built into this and fully expect we'll do that through both gross margin expansion as we've done but continue to gain leverage in the P&L where appropriate."
Phil Boudreau, Executive Vice President, Finance and Chief Financial Officer
Strategic Positioning
1. Nutrition Portfolio Recalibration
Abbott is prioritizing a transition from price-led to volume-led growth in its nutrition business, responding to consumer pushback and volume declines. Leadership initiated targeted price reductions and promotions across key markets in Q4, with early signs of improved demand elasticity. The company expects a challenging first half as these changes flow through, but is banking on a return to growth in H2 2026, supported by at least eight new product launches and a renewed focus on innovation. This marks a strategic shift from the pandemic-era focus on supply chain and pricing to a more sustainable, consumer-oriented model.
2. Medical Devices as Growth Engine
Medical devices have become Abbott’s primary engine for both revenue and margin expansion, with diabetes care, electrophysiology, and structural heart franchises leading the charge. The CGM business continues to gain share across all patient segments, and upcoming launches such as the dual glucose-ketone sensor and expanded PFA portfolio are expected to drive further adoption. The rhythm management and vascular segments, often overlooked, are also delivering above-market growth thanks to successful product innovation and market development efforts.
3. Diagnostics Stabilization and Emerging Markets
Diagnostics is stabilizing after COVID and China VBP headwinds, with CoreLab growth accelerating as these one-time drags are lapped. Management expects mid-single-digit global growth in diagnostics, with ex-China markets tracking 7-8% annually. EPD continues to capitalize on biosimilar launches and demographic tailwinds in emerging markets, providing a consistent high-single-digit growth anchor for the portfolio.
4. Capital Allocation and Exact Sciences Integration
Abbott’s capital allocation remains focused on medtech and diagnostics, with the Exact Sciences acquisition expected to add a new high-growth vertical in cancer diagnostics. Management reiterated commitment to a growing dividend and modest leverage post-close, with near-term M&A likely limited to tuck-in deals. Nutrition is not expected to require inorganic investment for recovery, as internal product launches and pricing resets are seen as sufficient.
5. Margin and Pipeline Discipline
Margin expansion remains a key pillar, with management targeting 50-70 basis points of annual operating margin improvement through a combination of gross margin gains and SG&A leverage. Abbott’s pipeline cadence, particularly in devices and diagnostics, is designed to support sustained high-single-digit top-line and double-digit bottom-line growth, reinforcing its investment identity.
Key Considerations
Abbott’s Q4 and 2026 outlook reflect a deliberate tradeoff: accepting near-term nutrition weakness to protect long-term brand and volume health, while doubling down on medical device and diagnostics innovation to drive margin and earnings growth. The company’s diversified business model, with balanced exposure to consumer, hospital, and emerging market channels, provides resilience but also requires deft execution across very different end markets.
Key Considerations:
- Nutrition Volume Recovery Timeline: Success of pricing resets and new product launches in reigniting volume growth will be critical for H2 2026 and beyond.
- Device Pipeline Execution: Timely regulatory approvals and commercial launches (e.g., dual glucose-ketone sensor, Volt PFA, TactiFlex Duo) are essential for sustaining device momentum.
- Diagnostics China Stability: Stabilizing the diagnostics business in China post-VBP is key to unlocking global CoreLab growth acceleration.
- Exact Sciences Integration: Smooth integration and realization of growth synergies in cancer diagnostics will be closely watched by investors.
- Operating Margin Leverage: Continued cost discipline and product mix improvement are needed to offset macro and tariff headwinds.
Risks
Nutrition’s recovery remains exposed to consumer price sensitivity, competitive actions, and execution risk in new product launches. Diagnostics faces ongoing uncertainty in China, with additional VBP rounds possible. Device pipeline delays or regulatory setbacks could slow growth, while integration challenges with Exact Sciences may distract from core execution. Tariff and cost inflation, especially in nutrition and devices, remain persistent margin threats.
Forward Outlook
For Q1 2026, Abbott guided to:
- Adjusted EPS of $1.12 to $1.18
- Organic sales growth of 6.5% to 7.5% for the full year, with H1 weighted by nutrition reset and acceleration expected in H2
For full-year 2026, management maintained:
- Adjusted EPS growth of 10% at the midpoint
- Operating margin expansion of 50-70 basis points
Leadership highlighted factors including strong device and diagnostics pipelines, lapping of COVID and China headwinds, and the addition of Exact Sciences as drivers of accelerating growth into the back half of the year.
- Nutrition transition expected to weigh on H1, with volume recovery targeted for H2
- Device and diagnostics launches to support above-market growth in core franchises
Takeaways
Abbott’s Q4 signals a business in strategic transition, actively choosing to reset its nutrition business to restore long-term health, while leveraging medical device and diagnostics innovation to drive earnings and margin expansion.
- Device-Led Margin Expansion: Medical devices are now Abbott’s primary growth and margin engine, with a robust pipeline supporting continued outperformance.
- Nutrition Reset as a Calculated Risk: Management’s willingness to accept near-term pain in nutrition reflects a focus on long-term sustainability rather than short-term optics.
- 2026 Inflection Hinges on Execution: Success will depend on delivering new product launches, stabilizing diagnostics in China, and integrating Exact Sciences without distraction.
Conclusion
Abbott enters 2026 with accelerating momentum in its device and diagnostics franchises, offset by a deliberate nutrition reset that will test execution discipline. The company’s margin expansion and pipeline cadence provide resilience, but the next six months will be critical in demonstrating that the nutrition strategy shift can deliver the promised volume recovery and set a foundation for sustainable growth.
Industry Read-Through
Abbott’s experience highlights the risks of prolonged price-led growth in consumer health segments, with volume elasticity and brand health forcing a return to volume-centric strategies. Device innovation remains the primary earnings driver in diversified medtech, with robust pipelines and market development efforts essential for long-term differentiation. Diagnostics players must prepare for ongoing China VBP volatility, while emerging market exposure continues to provide a growth ballast. Capital allocation discipline—favoring high-growth verticals and margin accretive investments—sets the tone for sector peers seeking to balance short-term pressures with long-term positioning.